Nabriva Therapeutics AG - Stock Price History | NBRV
Historical daily share price chart and data for Nabriva Therapeutics AG since 2021 adjusted for splits. The latest closing stock price for Nabriva Therapeutics AG as of October 22, 2021 is 1.09.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
- The all-time high Nabriva Therapeutics AG stock closing price was 132.40 on September 18, 2015.
- The Nabriva Therapeutics AG 52-week high stock price is 5.70, which is 422.9% above the current share price.
- The Nabriva Therapeutics AG 52-week low stock price is 1.00, which is 8.3% below the current share price.
- The average Nabriva Therapeutics AG stock price for the last 52 weeks is 2.06.
|Nabriva Therapeutics AG Historical Annual Stock Price Data
||Average Stock Price
||Annual % Change
||Medical - Biomedical and Genetics
Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics' lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP).